PMGC HOLDINGS INC. Cost of Revenue
PMGC HOLDINGS INC. (ELAB) reported Cost of Revenue of $207.92 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2025-11-14
- PMGC HOLDINGS INC. cost of revenue for the quarter ending 2024-09-30 was $133.58K, a 29.14% decline year-over-year.
- PMGC HOLDINGS INC. cost of revenue for the quarter ending 2024-06-30 was $166.28K, a 53.70% increase year-over-year.
- PMGC HOLDINGS INC. cost of revenue for the quarter ending 2023-12-31 was $1.37M.
- PMGC HOLDINGS INC. cost of revenue for the quarter ending 2023-09-30 was $188.51K.
- PMGC HOLDINGS INC. cost of revenue for fiscal 2023 was $1.71M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2025-09-30 | $207.92K 10-Q · filed 2025-11-14 | |||
| 2024-09-30 | $133.58K 10-Q · filed 2024-11-14 | $299.85K derived: sum of 2 quarters · filed 2024-11-14 | $468.76K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $166.28K 10-Q · filed 2024-08-14 | $335.19K 10-Q · filed 2024-08-14 | ||
| 2023-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.56M derived: sum of 2 quarters · filed 2024-11-14 | $1.67M derived: sum of 3 quarters · filed 2024-11-14 | $1.71M 10-K · filed 2024-03-29 |
| 2023-09-30 | $188.51K 10-Q · filed 2024-11-14 | $296.69K derived: sum of 2 quarters · filed 2024-11-14 | $341.12K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $108.18K 10-Q · filed 2024-08-14 | $152.61K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |